Akili Interactive on Wednesday revealed earlier-than-expected top-line clinical trial results suggesting its video game treatment for attention deficit hyperactivity disorder is effective for adults.
That’s very good news for a company that’s racing to reach more patients in hopes of building a sustainable business.
Akili’s treatment, EndeavorRx, is a mobile device game set in space that’s specially designed to target attention and related cognitive functions. In 2020, the game was cleared by the Food and Drug Administration to treat ADHD in children ages 8 to 12, but Akili had always planned to target other populations. The new glimpse at the adult pivotal trial results follow positive data the company released earlier this year in a trial testing EndeavorRx with adolescents ages 13 to 17.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
